Measuring the Prevalence of Toxoplasmosis and Its Socio-economic Consequences

NCT05860998 | Unknown

• 1 other identifier: 2023-00366
• Study Type: observational
• Target: 120
• Locations: 0 countries
• Sites: N/A

Brief Summary

The investigators propose a fast and inexpensive procedure to determine the prevalence of the Toxoplasmosis infection (Toxoplasma Gondii) in the general population, using response times in a cognitive task instead of costly medical tests. Therefore, the investigators aim to measure the prevalence of Toxoplasmosis and its socio-economic consequences in the general population.

Conditions

Toxoplasmosis; Rhd

Keywords

Toxoplasmosis; Rhd; Development of diagnostic tests; Neglected parasitic infections; Economic impact parasitic infections

Outcome Measures

Primary Outcomes (2)

• Presence of Toxoplasma gondii IgG Antibodies

  Presence of Toxoplasma gondii IgG Antibodies

  6 months

• Classified as afflicted by Toxoplasma gondii using response times

  Classification based on a reaction-time task of whether the participant is considered as afflicted by Toxoplasma gondii.

  6 months

Secondary Outcomes (11)

• Big 5 personality trait

  6 months

• Sensation Seeking scale

  6 months

• Cognitive Reflection Test

  6 months

• Risk aversion

  6 months

• Time preference

  6 months

Study Arms (2)

Toxoplasmosis positive

Healthy students with RhD-Negative blood with Toxoplasma gondii IgG Antibodies

Diagnostic Test: Presence of Toxoplasma gondii IgG Antibodies

Toxoplasmosis negative

Healthy students with RhD-Negative blood without Toxoplasma gondii IgG Antibodies

Diagnostic Test: Presence of Toxoplasma gondii IgG Antibodies

Interventions

Presence of Toxoplasma gondii IgG Antibodies DIAGNOSTIC_TEST

Testing for the presence of Toxoplasma gondii IgG Antibodies in participants blood.

Toxoplasmosis negative; Toxoplasmosis positive

Eligibility Criteria

• Age: 18 Years - 35 Years
• Sex: all
• Age Groups: Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

Participants will be recruited among the student population of the University of Zürich according to the established procedures of the SNS Laboratory.

You may qualify if:

• Ability and willingness to participate in the study.
• Declaration of consent.
• Having RhD-Negative blood. This is because only RhD-negative blood type become slower when afflicted by Toxoplasmosis. Hence, the proposed analysis can only be performed on RhD-Negative people.
• Good English language skills (at least C1, to ensure understanding of all instructions and the declaration of consent).

You may not qualify if:

• Inability to give the declaration of consent.
• Any neurological disorders
• Reduced general health / chronic diseases (e.g. autoimmune disease, severe cardiovascular diseases, insulin-dependent diabetes, severe depression); chronic pain disorders

Sponsors & Collaborators

• University of Zurich: lead

MeSH Terms

Conditions

Toxoplasmosis; Rheumatic Heart Disease

Condition Hierarchy (Ancestors)

Coccidiosis; Protozoan Infections; Parasitic Diseases; Infections; Rheumatic Fever; Streptococcal Infections; Gram-Positive Bacterial Infections; Bacterial Infections; Bacterial Infections and Mycoses; Heart Diseases; Cardiovascular Diseases

Central Study Contacts

Carlos Alós-Ferrer, PhD

CONTACT

798667160; carlos.alos-ferrer@econ.uzh.ch

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: April 26, 2023
• First Posted: May 16, 2023
• Study Start: June 26, 2023
• Primary Completion: July 30, 2023
• Study Completion: July 30, 2023
• Last Updated: May 18, 2023

Record last verified: 2023-05